Arcus Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In millions, except per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2024	2023	2024	2023
Revenues:
License and development services revenue (Includes $23, $18, $179 and $54 from a related party)	$41	$22	$204	$58
Other collaboration revenue (Includes $7, $10, $28 and $28 from a related party)	7	10	28	28
Total revenues	48	32	232	86
Operating expenses:
Research and development (Includes $2, $22, $32 and $89 of net recoveries from a related party)	123	82	347	247
General and administrative	30	30	92	88
Impairment of long-lived assets (see Note 12, Leases)	—	—	20	—
Total operating expenses	153	112	459	335
Loss from operations	(105)	(80)	(227)	(249)
Non-operating income (expense):
Interest and other income, net	14	12	40	30
Interest expense	(1)	(1)	(2)	(2)
Total non-operating income, net	13	11	38	28
Loss before income taxes	(92)	(69)	(189)	(221)
Income tax expense	—	(2)	—	(5)
Net loss	$(92)	$(71)	$(189)	$(226)
Net loss per share:
Basic and diluted	$(1.00)	$(0.94)	$(2.11)	$(3.07)
Shares used to compute net loss per share:
Basic and diluted	91.4	74.6	89.6	73.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.